Remidio, RetinaRisk partner to improve AI-driven Diabetic Retinopathy Screening

Remidio Innovative Solutions, an AI-powered ophthalmic diagnostics firm, has announced a strategic partnership with RetinaRisk, a health tech company from Iceland, to enhance risk-based diabetic retinopathy (DR) screening in India and Iceland.

This partnership brings together Remidio’s Medios DR AI for automated DR detection and RetinaRisk’s personalised risk triaging algorithm for progression to sight-threatening DR. Medios DR is an edge-AI solution that runs entirely on a smartphone without the need for internet access or cloud connectivity, offering real-time DR grading at the point of care. RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status.

From a public health perspective, this enables more cost-effective DR screening programmes by individualising screening intervals—extending the frequency for low-risk individuals while ensuring timely follow-up for high-risk cases.

“This collaboration moves us beyond detection into prediction, enabling care pathways that are not just reactive but truly preventative,” said Dr Anand Sivaraman, CEO, Remidio. 

Dr Rajiv Raman, Senior Consultant, Sankara Nethralaya, added, “In our validation study involving nearly 1,000 individuals with type 2 diabetes from the SNDREAMS cohort, a four-year longitudinal study done by Sankara Nethralaya, the RetinaRisk algorithm demonstrated strong predictive performance for sight-threatening diabetic retinopathy (STDR), with the AUC improving to 0.853 when local clinical factors like albuminuria and baseline DR severity were incorporated. Notably, this personalised, risk-based model enabled a 56 per cent reduction in screening frequency and led to annual cost savings of over 50 per cent for patients without DR and 41 per cent for those with NPDR.”

Aegir Thor Steinarsson, CEO, RetinaRisk commented, “Together, we are demonstrating that AI-enabled screening can be made accessible, personalised, and impactful in both developed and emerging healthcare systems.”

The partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India, aiming to create a scalable framework for prioritised referrals, longitudinal tracking, and reduced vision loss due to DR.